Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

2.010 -0.020 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 118,059
Open 1.980
Bid (Size) 1.310 (1)
Ask (Size) 2.270 (313)
Prev. Close 2.030
Today's Range 1.960 - 2.070
52wk Range 1.120 - 4.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
From Inhibikase Therapeutics
Via GlobeNewswire

Performance

YTD
-38.9%
-38.9%
1 Month
+5.8%
+5.8%
3 Month
-22.7%
-22.7%
6 Month
+2.0%
+2.0%
1 Year
+16.2%
+16.2%

More News

Read More
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Announces Expansion of Senior Leadership Team
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
From Inhibikase Therapeutics
Via GlobeNewswire
This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Dow Surges 350 Points; US Crude Oil Stocks Increase
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August
Via Benzinga
Exposures Fossil Fuels
Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today
Via Benzinga
Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
From Inhibikase Therapeutics
Via GlobeNewswire
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Inhibikase Therapeutics, Inc. - Common Stock publicly traded?
Yes, Inhibikase Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Inhibikase Therapeutics, Inc. - Common Stock trade on?
Inhibikase Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock?
The ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock is IKT on the Nasdaq Stock Market
What is the current price of Inhibikase Therapeutics, Inc. - Common Stock?
The current price of Inhibikase Therapeutics, Inc. - Common Stock is 2.010
When was Inhibikase Therapeutics, Inc. - Common Stock last traded?
The last trade of Inhibikase Therapeutics, Inc. - Common Stock was at 05/16/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.